吉西他滨联合希罗达治疗蒽环类和紫杉类药物治疗失败乳腺癌肝转移的疗效分析

目的观察吉西他滨联合希罗达治疗蒽环类和紫杉类药物治疗失败乳腺癌肝转移的疗效。方法收治36例女性乳腺癌化疗后合并肝转移患者,采取吉西他滨1000 mg/m2,静脉滴注,第1,8天;希罗达2000 mg/m2,口服,第1～14天。3周为1个周期。连续做2个周期化疗后评价疗效。结果 36例患者CR 0例,PR 6例(16.7%),SD 9例(25.0%),PD 21例(58.3%),有效率(CR+PR)为16.7%(6/36),临床获益率(CR+PR+SD)为41.7%(15/36)。不良反应:白细胞减少Ⅰ～Ⅱ度占72.2%(26/36),Ⅲ～Ⅳ度占16.7%(6/36),血小板减少Ⅰ～Ⅱ度占44.4%(16/36),Ⅲ～Ⅳ度占2.8%(1/36)。消化道反应Ⅰ～Ⅱ度发生率44.4%(16/36),Ⅲ～Ⅳ度恶心呕吐发生率为0。Ⅲ～Ⅳ度腹泻发生率2.8%(1/36)。手足综合征Ⅰ～Ⅱ度发生率19.4%(7/36)。结论对蒽环类和紫杉类药物治疗失败乳腺癌肝转移患者,在可供选择的方案非常少的情况下,吉西他滨联合希罗达化疗方案是一种不错的选择。

Analysis on efficacy of gemcitabine combined with xeloda in treating patients with liver metastases of breast cancer after anthracycline-based and taxane combinations drug treatment failure

Objective To observe curative effect of gemcitabine combined with xeloda in treating patients with liver metastases of breast cancer after anthracycline-based and taxane combinations drug treatment failure.Methods Thirty-six female cases of breast cancer with liver metastases were given intravenous gemcitabine 1000 mg/m2 on the day 1 and 8,and oral xeloda 2000 mg/m2 on the days 1-14,three weeks as a cycle.The curative effect of chemotherapy was evaluted after continuous treatment for 2 cycles.Results In 36 ...